RTW Investments LLC increased its position in shares of AveXis, Inc. (NASDAQ:AVXS) by 73.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 825,980 shares of the company’s stock after buying an additional 349,613 shares during the period. AveXis accounts for about 8.4% of RTW Investments LLC’s holdings, making the stock its 3rd largest position. RTW Investments LLC’s holdings in AveXis were worth $34,039,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. raised its position in AveXis by 98.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 14,609 shares of the company’s stock valued at $556,000 after buying an additional 7,252 shares during the last quarter. GAM Holding AG purchased a new position in AveXis during the third quarter valued at about $1,212,000. Ameriprise Financial Inc. purchased a new position in AveXis during the second quarter valued at about $1,321,000. TD Asset Management Inc. raised its position in AveXis by 377.1% in the third quarter. TD Asset Management Inc. now owns 32,444 shares of the company’s stock valued at $1,337,000 after buying an additional 25,644 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in AveXis by 7.1% in the third quarter. JPMorgan Chase & Co. now owns 37,150 shares of the company’s stock valued at $1,531,000 after buying an additional 2,475 shares during the last quarter. Institutional investors own 68.31% of the company’s stock.
Shares of AveXis, Inc. (NASDAQ:AVXS) traded up 1.45% during mid-day trading on Monday, reaching $58.63. 27,966 shares of the company’s stock were exchanged. AveXis, Inc. has a one year low of $17.40 and a one year high of $72.72. The firm’s market capitalization is $1.62 billion. The stock has a 50-day moving average of $53.63 and a 200 day moving average of $48.35.
AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, November 10th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by $0.18. On average, analysts forecast that AveXis, Inc. will post ($3.51) EPS for the current fiscal year.
This story was originally posted by sleekmoney and is the property of of sleekmoney. If you are accessing this story on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The correct version of this story can be read at http://sleekmoney.com/avexis-inc-avxs-is-rtw-investments-llcs-3rd-largest-position/1658156.html.
Several research analysts have issued reports on the stock. Chardan Capital set a $85.00 price target on shares of AveXis and gave the stock a “buy” rating in a report on Sunday, December 25th. Zacks Investment Research lowered shares of AveXis from a “buy” rating to a “hold” rating in a report on Tuesday, November 15th. BMO Capital Markets reiterated an “outperform” rating and issued a $80.00 price objective (up previously from $52.00) on shares of AveXis in a research note on Wednesday, November 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $79.00 price objective (up previously from $71.00) on shares of AveXis in a research note on Monday, November 14th. Finally, Stifel Nicolaus began coverage on shares of AveXis in a research note on Monday, November 14th. They issued a “hold” rating and a $65.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $70.22.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/avexis-inc-avxs-is-rtw-investments-llcs-3rd-largest-position/1658156.html
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.